Anti-Cancer Agent Herceptin Approved for Additional Indication of Salivary Gland Cancer

PRESS RELEASE Corporate Announcements

03/12/2021

Chugai Pharmaceutical Co., Ltd.

TOKYO, November 25, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it obtained approval from the Ministry of Health, Labour and Welfare (MHLW) for the anti-HER2 humanized monoclonal antibody Herceptin® Injection 60 and 150 [generic name: trastuzumab] for the additional indication of advanced or recurrent HER2-positive salivary gland cancer not amenable to curative resection. Orphan drug designation had been granted by the MHLW on March 11, 2021 for this indication.

Related News

Trastuzumab deruxtecan (DS-8201/T-DXd) ได้รับการรับรอง “Breakthrough Therapy Designation" จาก FDA ในฐานะ second-line treatment สำหรับผู้ป่วยมะเร็งเต้านม HER2-positive

Daiichi Sankyo Co., Ltd. (สำนักงานใหญ่: Chuo-ku, Tokyo ต่อจากนี้จะเรียกว่า "Daiichi") และ AstraZeneca (สำนักงานใหญ่: Cambridge, สหราชอาณาจักร) ได้เปิด...

29/10/2021

PRESS RELEASE FDA Approval

Study shows efficacy of dual-HER2 targeted therapy for patients with HER2-positive colorectal cancer

Investigator-initiated trial based on GI-SCREEN-Japan/GOZILA study may lead to the world's first effective treatment for HER2-positive colorectal canc...

15/11/2021

PRESS RELEASE Research Findings

ENHERTU® Additional Analyses Further Reinforce Groundbreaking Efficacy in Patients with HER2 Positive Metastatic Breast Cancer

Tokyo, Munich and Basking Ridge, NJ – (December 9, 2021) – New results from the DESTINY-Breast03 phase 3 trial showed that ENHERTU® (trastuzumab derux...

16/12/2021

PRESS RELEASE Research Findings

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric Cancer

Tokyo, Munich– (November 3, 2021) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EM...

09/11/2021

PRESS RELEASE Corporate Announcements

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509 15th floor South Sathorn road Yannawa Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us